Respiratory infections in oncology are both common and potentially severe. However, there is still a gap in the literature, regarding the epidemiology of viral respiratory infections in children with cancer. We prospectively enrolled 224 patients, from September 2012 to August 2015. The cohort included children with hematologic or solid malignancies receiving chemotherapy, or undergoing hemopoietic stem cell transplantation, outpatients/inpatients exhibiting signs/symptoms of febrile/afebrile upper/lower respiratory infection. Viral infection was diagnosed by detection of ≥1 viruses from a sample at time of enrollment, using the CLART®PneumoVir kit (GENOMICA, Spain). Α detailed questionnaire including demographics and medical history was also completed. Samples were processed in batches, results were communicated as soon as they became available. Children recruited in whom no virus was detected composed the no virus detected group. Viral prevalence was 38.4% in children presenting with respiratory illness. A single virus was found in 30.4%, with RSV being the most frequent. Viral coinfections were detected in 8%. Children with viral infection were more likely to be febrile upon enrollment and to present with lower respiratory signs/symptoms. They had longer duration of illness and they were more likely to receive antibiotics/antifungals. Only 22% of children with influenza received oseltamivir. Mortality was low (2.7%), however, pediatric intensive care unit (PICU) admission and death were correlated with virus detection. In our study mortality was low and PICU admission was related to virus identification. Further research is needed to clarify whether antibiotics in virus-proven infection are of value and underline the importance of oseltamivir’s timely administration in influenza.
Background: Nontuberculous mycobacteria (NTM) are opportunistic pathogens responsible for chronic pulmonary infections, primarily affecting individuals with underlying conditions such as cystic fibrosis (CF). The aim of this review is to present the epidemiological profile of NTM in CF patients, with a focus on incidence, prevalence, predominant species, and geographic distribution. Methods: The search included cross-sectional, retrospective, and prospective observational studies published in English that reported epidemiological data concerning the isolation and/or infection of individuals with CF by NTM. NTM infection was defined as the isolation of any NTM species at least once per patient. Out of an initial 1120 references identified in PubMed, and following the application of exclusion criteria based on PRISMA guidelines, a total of 78 studies were included. Results: The reported prevalence of NTM in CF patients ranges globally from 0% to 40.9%. This wide variability is attributed to population heterogeneity, study period, and geographical region. Of the studies included, 30 were conducted in Europe and 25 in the U.S.A. Mycobacterium abscessus and the Mycobacterium avium complex (MAC) were the most commonly isolated species, with MAC being more prevalent in older individuals. The incidence of NTM pulmonary disease was high, with the majority of cases being associated with M. abscessus. Although emerging evidence suggests that CFTR modulator therapy may reduce the risk of NTM isolation and/or disease, current data remain limited. Conclusions: Nontuberculous mycobacteria are significant pathogens in patients with cystic fibrosis, with a negative impact on respiratory health.
Background: Highly effective CFTR modulator therapy has substantially changed the clinical course of cystic fibrosis (CF), but the magnitude of treatment response may vary according to baseline lung function. We evaluated the real-world effects of elexacaftor/tezacaftor/ivacaftor (ETI) in people with CF aged >6 years across a broad range of baseline lung function. Methods: In this observational study, 62 people with CF (23 male; age range 7.8–36.8 years) who were eligible for ETI according to genotype underwent assessment at treatment initiation and after 6 months. Assessments included spirometry, respiratory oscillometry, body composition and biochemical measurements. Results: Mean ppFEV1 increased from 94% at baseline to 108% after 6 months (p < 0.001), while mean FEF25–75 increased from 77% to 100% predicted (p < 0.001). Lower baseline ppFEV1 was associated with a greater ppFEV1 response (r = −0.596, p < 0.001), and baseline ppFEV1 remained the only significant factor associated with ppFEV1 change in multivariable analysis (β = −0.21, p = 0.006). Improvement was greater among participants with baseline ppFEV1 < 90%, although a measurable increase was also observed in those with ppFEV1 ≥ 90%. BMI increased significantly. HDL and LDL cholesterol increased (p = 0.007 and p = 0.011, respectively), whereas C-reactive protein decreased (p < 0.001). Changes in oscillometry were modest and provided limited additional information beyond spirometry in this cohort. Conclusions: ETI was associated with significant improvements in lung function in people with CF aged >6 years, including those with preserved baseline spirometry. The magnitude of ppFEV1 improvement was greatest in participants with lower baseline ppFEV1. These findings support measurable physiological benefit from ETI across a broad spectrum of baseline lung function, while highlighting the need for longer-term studies of outcomes in people with near-normal spirometry.